drugset / Trial / NCT02257008

Effect of Different Boosting Agents on Pharmacokinetics of BILR 355 BS Dissolved in Polyethylene Glycol 400 (PEG 400) in Healthy Male Volunteers

NCT02257008

Phase 1 Completed 44 enrolled Boehringer Ingelheim
RandomizedParallel-groupOpen-labelTreatment

Summary

Assessment of the effect of different boosting agents on pharmacokinetics of a single dose of BILR 355 BS dissolved in PEG 400

Timeline

Start
2003-03
Primary completion
2003-12
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Atazanavir Other / unclassified
Subject BILR 355 BS Unknown 5 mg Oral
Subject BILR 355 BS Unknown 12.5 mg Oral
Subject Nelfinavir Other / unclassified
Subject Ritonavir Other / unclassified

Indications

No indication recorded.